Nanoform Finland Plc launched the next generation of its STARMAP AI (artificial intelligence) platform, v2.0. The technology utilizes sparse-data AI to augment experimental results from its CESS nanoparticle engineering process with detailed expert knowledge, allowing reliable predictions to be made regarding partners' potential success of nanoforming their drug molecules. CESS is a nanoparticle platform technology which produces pure homogeneous drug particles from solution in an excipient-free process. By reducing the particle size e.g., from 10 microns to 50 nm, the specific surface area can be increased by as much as 1000-fold, thereby improving dissolution rate, solubility, and bioavailability. Consequently, Nanoform can help pharma partners progress molecules into development that otherwise may not have been possible. It also opens up exciting possibilities for a wide range of novel drug delivery applications. STARMAP is a digital version of the CESS technology that enables in silico experiments in large quantities, creating fast predictions of which molecules should be nanoformed. This is important since there are more potential drug molecules than particles in the known universe. STARMAP can be a powerful tool for pharma partners to pick suitable drug candidates for further development from their large libraries. The benefits might include faster path to market and new possibilities for broadening and deepening drug pipelines while simultaneously increasing the probability of drug development success. The STARMAP platform can have wide applicability in drug discovery and development as well as in lifecycle management for existing marketed drugs and 505b2-like product development strategies.